Somatostatin receptor PET/CT with radiolabelled antagonist is twice as effective as the agonist for detecting liver metastases: Results of a phase I/II study comparing 68Ga-OPS202 with 68Ga-DOTATOC PET/CT in gastro-entero-pancreatic neuroendocrine tumor p

#1324

Introduction: 68Ga-DOTATOC PET/CT is a reference method for imaging somatostatin receptor (sst) expressing tumors (NET). Presence of liver metastases impacts on patient management and prognosis.

Aim(s): To investigate safety and diagnostic accuracy of 68Ga-OPS202, a radiolabeled sst antagonist for PET/CT imaging of gastroenteropancreatic (GEP) NET (ClinicalTrials.gov NCT02162446).

Materials and methods: Twelve metastatic G1/G2 GEP-NET patients were enrolled in a prospective phase I/II imaging study to investigate two single doses of 68Ga-OPS202 (A: 15μg & B: 50μg) in comparison with 68Ga-DOTATOC PET/CT. Scans were reviewed by 2 independent blinded readers. Follow-up imaging and biopsy were used as standard of reference.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Nicolas G

Authors: Nicolas G, Schreiter N, Kaul F, Uiters J, Mena R,

Keywords: somatostatin antagonist, PET,